Boston Scientific (NYSE:BSX)‘s stock had its “hold” rating reiterated by stock analysts at Oppenheimer in a note issued to investors on Tuesday.

Other analysts have also issued research reports about the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $37.00 price objective on shares of Boston Scientific in a research note on Thursday, July 26th. Guggenheim reiterated a “buy” rating and issued a $43.00 price objective on shares of Boston Scientific in a research note on Friday, July 27th. Jefferies Financial Group reiterated a “hold” rating and issued a $34.00 price objective on shares of Boston Scientific in a research note on Thursday, July 26th. Sanford C. Bernstein started coverage on shares of Boston Scientific in a research note on Wednesday, June 27th. They issued an “outperform” rating and a $38.00 price objective for the company. Finally, Argus lifted their price target on shares of Boston Scientific to $41.00 and gave the company a “buy” rating in a research report on Wednesday, September 5th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the stock. Boston Scientific currently has an average rating of “Buy” and a consensus price target of $36.43.

Boston Scientific stock opened at $38.40 on Tuesday. The company has a market cap of $52.23 billion, a price-to-earnings ratio of 30.48, a PEG ratio of 2.63 and a beta of 0.63. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.83 and a quick ratio of 0.60. Boston Scientific has a 52-week low of $24.54 and a 52-week high of $38.49.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07. The company had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.47 billion. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. Boston Scientific’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 EPS. analysts forecast that Boston Scientific will post 1.39 earnings per share for the current year.

In other Boston Scientific news, SVP John Bradley Sorenson sold 10,000 shares of Boston Scientific stock in a transaction on Monday, September 10th. The shares were sold at an average price of $35.86, for a total transaction of $358,600.00. Following the transaction, the senior vice president now directly owns 44,636 shares of the company’s stock, valued at approximately $1,600,646.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jeffrey B. Mirviss sold 33,512 shares of Boston Scientific stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $34.00, for a total transaction of $1,139,408.00. The disclosure for this sale can be found here. Insiders have sold a total of 175,250 shares of company stock worth $6,196,995 over the last ninety days. Insiders own 0.73% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC boosted its holdings in shares of Boston Scientific by 3.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock worth $1,671,000 after buying an additional 1,547 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of Boston Scientific by 103.8% in the 2nd quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 1,594 shares during the last quarter. Somerset Group LLC boosted its holdings in shares of Boston Scientific by 3.4% in the 2nd quarter. Somerset Group LLC now owns 49,838 shares of the medical equipment provider’s stock worth $1,630,000 after buying an additional 1,638 shares during the last quarter. Bainco International Investors boosted its holdings in shares of Boston Scientific by 0.8% in the 2nd quarter. Bainco International Investors now owns 208,514 shares of the medical equipment provider’s stock worth $6,818,000 after buying an additional 1,729 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Boston Scientific by 2.7% in the 1st quarter. Commonwealth Equity Services LLC now owns 71,279 shares of the medical equipment provider’s stock worth $1,947,000 after buying an additional 1,850 shares during the last quarter. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.